These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29998370)

  • 1. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA
    Kim SR; Lee YH; Kang ES; Cha BS; Lee BW
    Diabetes Ther; 2017 Jun; 8(3):601-609. PubMed ID: 28332143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
    Wilding J; Bailey C; Rigney U; Blak B; Beekman W; Emmas C
    Diabetes Ther; 2016 Dec; 7(4):695-711. PubMed ID: 27585582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency.
    Raji A; Xu ZJ; Lam RLH; O'Neill EA; Kaufman KD; Engel SS
    Diabetes Ther; 2020 Oct; 11(10):2419-2428. PubMed ID: 32852696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
    Gordon J; Danne T; Beresford-Hulme L; Bennet H; Tank A; Edmonds C; Thorén F; Scheerer MF; McEwan P
    Diabetes Ther; 2020 May; 11(5):1135-1146. PubMed ID: 32274678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM.
    Nada AM; Younan MA
    Ther Adv Endocrinol Metab; 2021; 12():2042018821995364. PubMed ID: 33796252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus.
    Hayakawa T; Kato KI; Kobuchi S; Kataoka K; Sakaeda T
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus.
    Iwasaki T; Yoneda M
    Diabetol Int; 2016 Mar; 7(1):77-82. PubMed ID: 30603246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus.
    Cho HA; Jung YL; Lee YH; Lee YC; Lee JE; Lee SJ; Jeong SJ; Kim CH
    J Obes Metab Syndr; 2017 Jun; 26(2):107-113. PubMed ID: 31089504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.
    Sosale B; Sosale A; Bhattacharyya A
    Diabetes Ther; 2016 Dec; 7(4):765-776. PubMed ID: 27761881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin--do we need it registered for type 2 diabetes?
    Doggrell SA; Tuli R
    Expert Opin Pharmacother; 2014 Aug; 15(11):1631-5. PubMed ID: 24998153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes.
    Liu J; Chang X; Ding X; He X; Wang J; Wang G
    Diabetol Metab Syndr; 2023 Dec; 15(1):251. PubMed ID: 38044448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip.
    Kawano R; Haze T; Fujiwara A; Haruna A; Ozawa M; Kobayashi Y; Saka S; Hirawa N; Tamura K
    Clin Exp Nephrol; 2024 Jul; ():. PubMed ID: 38970649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
    Yavin Y; Mansfield TA; Ptaszynska A; Johnsson K; Parikh S; Johnsson E
    Diabetes Ther; 2016 Mar; 7(1):125-37. PubMed ID: 26758563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.